Guardant Health, Inc. announced that its Shield blood test for colorectal cancer (CRC) screening was named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing urgent global challenges.
This honor recognizes the groundbreaking innovation of the Shield blood test, which is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. CRC is the second leading cause of cancer-related deaths in the U.S., with a 91% five-year survival rate if caught early.
AmirAli Talasaz, Guardant Health co-CEO, stated that Shield provides a more convenient and pleasant screening option for millions who delay recommended screening due to traditional methods. This award highlights the test's potential to increase overall screening rates, detect more cancers at an early stage, and ultimately save lives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.